363 related articles for article (PubMed ID: 16895513)
1. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
2. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
3. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
5. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
6. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
[TBL] [Abstract][Full Text] [Related]
7. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
Dhainaut JF;
Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
[TBL] [Abstract][Full Text] [Related]
8. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
[TBL] [Abstract][Full Text] [Related]
9. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
Short MA; Schlichting D; Qualy RL
Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
[TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
12. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
13. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials in severe sepsis with drotrecogin alfa (activated).
Laterre PF
Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
17. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
20. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
